Cited by 172Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health EffectsSubstance Abuse Treatment and Outcomes

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease

Open access

Younossi, Zobair M., Stepanova, Maria, Ong, Janus, Yilmaz, Yusuf, Duseja, Ajay, Eguchi, Yuichiro, El Kassas, Mohamed, Castellanos-Fernandez, Marlen, George, Jacob, Jacobson, Ira M., Bugianesi, Elisabetta, Wong, Vincent Wai-Sun, Arrese, Marco, de Ledinghen, Victor, Romero-Gomez, Manuel, Mendez-Sanchez, Nahum, Ahmed, Aijaz, Wong, Robert, Papatheodoridis, Georgios, Serfaty, Lawrence, Younossi, Issah, Nader, Fatema, Ziayee, Mariam, Afendy, Arian·2019·Clinical Gastroenterology and Hepatology

DOI 10.1016/j.cgh.2018.11.033

Open this paper in CoChat — free account Open PDF

Abstract

Background & aims Non-alcoholic and alcohol-related fatty liver disease are overlapping diseases in which metabolic syndrome and alcohol consumption each contribute to progressive liver disease. We aimed to assess the effects of alcohol consumption and metabolic syndrome on mortality in individuals with fatty liver.Methods We searched the National Health and Nutrition and Examination Survey III for adults (20-74 years old) with hepatic steatosis, detected by ultrasound, for whom mortality and follow-up data were available. We collected data from the alcohol use questionnaire (self-reported number of days a participant drank alcohol; the number of drinks [10 g alcohol] per day on a drinking day; the number of days the participant had 5 or more drinks) and calculated the average amount of alcohol consumption in drinks/day for each participant during the year preceding enrollment. Excessive alcohol consumption for men was >3 drinks/day and for women was >1.5 drinks/day. We also collected clinical data, and mortality data were obtained from the National Death Index. Demographic and clinical parameters were compared among consumption groups using the χ 2 test for independence or survey regression models. We used Cox proportional hazard models to identify independent predictors of all-cause and cause-specific mortality.Results The study cohort included 4264 individuals with hepatic steatosis (mean age, 45.9 years; 51% male; 76% white; 46% with metabolic syndrome; 6.2% with excessive alcohol use). There was no significant difference in mean age between individuals with vs without excessive alcohol consumption (P=.65). However, overall mortality was significantly higher among participants with excessive alcohol consumption (32.2%) vs participants with non-excessive alcohol use (22.2%) after mean 20 years of follow up (P=.003), as well as after 5 years of follow up. In multivariate analysis, the presence of metabolic syndrome (adjusted hazard ratio [aHR], 1.43; 95% CI, 1.12-1.83) and excessive alcohol consumption (aHR, 1.79; 95% CI, 1.21-2.66) were independently associated with an increased risk of death in individuals with hepatic steatosis; any lower average amount of alcohol consumption was not associated with mortality (all P>.60). In a subgroup analysis, the association of excessive alcohol use with mortality was significant in individuals with metabolic syndrome (aHR, 2.46; 95% CI, 1.40-4.32) but not without it (P=.74).Conclusion In review of data from the National Health and Nutrition and Examination Survey III, we associated alcohol consumption with increased mortality in participants with fatty liver and metabolic syndrome. These findings indicate an overlap between non-alcoholic and alcohol-related fatty liver disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2018.11.033

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,496
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Wong, R. J., Aguilar, M. E. F., Cheung, R. C., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,861
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D. B., Blissett, R., Henry, L. L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,308
Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008
Younossi, Z. M., Stepanova, M., Afendy, M., Fang, Y. H., Younossi, Y., Mir, H., & Srishord, M. K. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,072
Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009
Younossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802
Self-citation
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
Younossi, Z., Stepanova, M., Ong, J., Jacobson, I., Bugianesi, E., Duseja, A., Eguchi, Y., Wong, V., Negro, F., Yılmaz, Y., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.05.057 · Cited by 702
The National Cholesterol Education Program–Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the Metabolic Syndrome as Predictors of Incident Cardiovascular Disease and Diabetes
Lorenzo, C., Williams, K., Hunt, K. J., & Haffner, S. M. (2006) · Diabetes Care · doi:10.2337/dc06-1414 · Cited by 669

Flagged first, then by citations

Show all 23 references

Sorted by citations

Items 101–172 of 172

Impact of metabolic risk factors on hepatic and cardiac outcomes in patients with alcohol- and non-alcohol-related fatty liver disease
Lim, J. H., Sang, H., & Kim, H. I. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100721 · Cited by 10
“10,14,43 By contrast, one meta-analysis reported that the consumption of alcohol increased hepatic outcomes under conditions accompanied by MetRs, such as BMI.”
Different minimal alcohol consumption in male and female individuals with metabolic dysfunction‐associated fatty liver disease
Zhu, Y., Xu, X., Fan, Z., Ma, X., Rui, F., Ni, W., Hu, X., Gu, Q., Shi, J., Wu, C., et al. (2024) · Liver International · doi:10.1111/liv.15849 · Cited by 10
Association between advanced fibrosis in fatty liver disease and overall mortality based on body fat distribution
Chung, G. E., Heo, N. J., Kim, D., Kwak, M., Yim, J. Y., Kim, J. S., & Ahmed, A. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14778 · Cited by 9
Alcohol consumption in patients with nonalcoholic fatty liver disease: yes, or no?
Protopapas, A. A. (2021) · Annals of Gastroenterology · doi:10.20524/aog.2021.0641 · Cited by 9
Contemporary Trends in Hospitalizations for Comorbid Chronic Liver Disease and Substance Use Disorders
Desai, A. P., Greene, M., Nephew, L. D., Orman, E. S., Ghabril, M., Chalasani, N., & Menachemi, N. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000372 · Cited by 9
Do Associations Between Alcohol Use and Alcohol Use Disorder Vary by Weight Status? Results From the National Epidemiologic Survey on Alcohol and Related Conditions‐III
White, G. E., Richardson, G. A., Mair, C., Courcoulas, A. P., & King, W. C. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14071 · Cited by 9
Alcohol use disorders and liver fibrosis: an update
Caputo, F., Penitenti, F., Bergonzoni, B., Lungaro, L., Costanzini, A., Caio, G., GIORGIO, R. D., Ambrosio, M. R., Zoli, G., & Testino, G. (2024) · Minerva Medica · doi:10.23736/s0026-4806.24.09203-6 · Cited by 8
Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus
Tan, E. Z., Lai, L. L., Vethakkan, S. R., Mustapha, N. R. N., Mahadeva, S., & Chan, W. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15160 · Cited by 8
Association of the Metabolic Dysfunction-Associated Fatty Liver Disease with Serum Uric Acid-to-Creatinine Ratio
Han, A. L., & Lee, H. K. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0013 · Cited by 8
“13,34 A meta-analysis of 17 studies investigated whether this relationship follows a continuous dose–response pattern or has a threshold, and showed that alcohol consumption had a far greater impact on mortality from cirrhosis than on morbidity.”
Diet and non-alcoholic fatty liver disease, a short narrative review
Kwanten, W. J. (2023) · Acta gastro-enterologica belgica · doi:10.51821/86.2.11547 · Cited by 9
Distribution of Fibrosis‐4 index and vibration‐controlled transient elastography‐derived liver stiffness measurement for patients with metabolic dysfunction‐associated steatotic liver disease in health check‐up
Ogawa, Y., Tomeno, W., Imamura, Y., Baba, M., Ueno, T., Kobayashi, T., Iwaki, M., Nogami, A., Kessoku, T., Honda, Y., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14117 · Cited by 7
Association of steatotic liver disease with all-cause and cardiovascular mortality among prehypertensive or hypertensive patients
Yan, S., Li, Q., Cao, W., Pei, H., Zhen, S., Wu, Q., Yang, X., & Liang, F. (2025) · Journal of Global Health · doi:10.7189/jogh.15.04003 · Cited by 7
“Additionally, alcohol can accelerate lipid accumulation via the reduction of mitochondrial β-oxidation of fatty acids and very low-density lipoprotein secretion in the liver [ 29 ].”
Diet Habits and Hepatocellular Carcinoma—Potential Implication for Clinical Practice
Matray, C., Debras, C., Chatziioannou, A. C., Perlemuter, G., Jenab, M., & Voican, C. S. (2025) · Nutrition Reviews · doi:10.1093/nutrit/nuaf129 · Cited by 7
Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study
Tateda, T., Iino, C., Sasada, T., Sato, S., Igarashi, G., Kawaguchi, S., Mikami, K., Endo, T., Sawada, K., Mikami, T., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277930 · Cited by 8
Liver health and the interplay between obesity, alcohol and bariatric surgery
Geerts, A. M., Onghena, L., & Lefere, S. (2023) · Acta gastro-enterologica belgica · doi:10.51821/86.2.11553 · Cited by 7
Role of Alcohol in Steatotic Liver Disease: Impact on Patients with Cardiometabolic Risk Factors
Capinha, F., Carvalhana, S. C., & Cortez‐Pinto, H. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08912-4 · Cited by 6
“[58] Furthermore, the association of excessive alcohol consumption with mortality was significant only in individuals with metabolic syndrome, although the authors justify that with sample size, that could not be large enough to capture milder effects which could still exist for lower amounts of…”
The Relationship between Mindfulness and Readiness to Change in Alcohol Drinkers
Hamza, E. A., Yoon, A., Liu, L., Garg, A., Richard, Y., Frydecka, D., Helal, A. A., & Moustafa, A. A. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20095690 · Cited by 9
Time to revise the definition of NAFLD: A purist vision
Mantovani, A. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.12.018 · Cited by 6
Machine learning for predicting all-cause mortality of metabolic dysfunction-associated fatty liver disease: a longitudinal study based on NHANES
Wang, X., Chen, H., Wang, L., & Sun, W. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03946-4 · Cited by 5
Non-metabolic causes of steatotic liver disease
Nasr, P., Jönsson, C., Ekstedt, M., & Kechagias, S. (2023) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2023.20 · Cited by 5
Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups
Fukuda, T., Okamoto, T., Fukaishi, T., Kawakami, A., Tanaka, M., Yamada, T., & Monzen, K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1392280 · Cited by 5
The evolving landscape of pediatric obesity and metabolic dysfunction-associated steatotic liver disease
Putri, R. R. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1675713 · Cited by 6
Steatotic liver disease as a risk enhancer in the presence of metabolic syndrome
Zeng, G., Wang, P., Xu, W., Li, Q., Li, T., Tian, Y., Huang, B., Grobbee, D. E., Cabezas, M. C., & Yuan, J. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf330 · Cited by 4
Subgroups of Steatotic Liver Disease Have Distinct Clinical Phenotypes
Pekarska, K., Burke, L., Rowe, I. A. C., & Parker, R. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.102587 · Cited by 3
Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD
Xiong, Z., Lin, R., Chen, B., Xin, X., Deng, T., Sun, Q., Hu, Y., Gan, L., & Feng, Q. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70286 · Cited by 3
Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021
Wang, Y., Oza, N., Leo, J., Choudhury, A. K., & Huang, D. Q. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0133 · Cited by 3
Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
Cainelli, F., Thao, T., Pung, C., & Vento, S. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00014 · Cited by 3
“In the first study (2), the authors searched the National Health and Nutrition and Examination Survey III for 20–74 year old individuals with liver steatosis (detected by ultrasound), for whom mortality and follow-up data were available, gathered data from the self-reported alcohol use questionnaire, and calculated th…”
BackgroundInfluential
Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
Pithani, K. D., & Vadhi, R. (2024) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2023.07.005 · Cited by 3
Alcohol and Metabolic Syndrome Interaction
Hashida, R., Golabi, P., Ong, J. P., Kawaguchi, T., & Younossi, Z. M. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.06.002 · Cited by 2
Treatment approaches for alcohol use disorder with metabolic dysfunction
Wagner, A. C., Jung, J., Pacher, P., & Lohoff, F. W. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108957 · Cited by 4
Integrating Alcohol Use Into MASLD Care: A Practical Guide for Diabetes and Obesity Care Teams
Alexopoulos, A., & Cusi, K. J. (2026) · Diabetes Care · doi:10.2337/dci26-0019 · Cited by 2
Association between Metabolic Syndrome and Substance Dependence: A Cross-Sectional Study in Kenya
Mbugua, S. M., Mecha, E. O., Kirira, P., Njoroge, M., Malala, B., Gitaka, J., Makokha, F., & Mwenda, C. S. (2022) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2022.4.3.1030 · Cited by 2
Binge drinking does not appear to have an adverse effect on non-alcoholic fatty liver disease: Findings from a study of four First Nations communities
Dascal, R., Rumbolt, C., Uhanova, J., Surina, D., Oketola, G., Beardy, B., & Minuk, G. Y. (2022) · Canadian Liver Journal · doi:10.3138/canlivj-2022-0013 · Cited by 2
Gesundheitsrisiko Alkohol – neue Empfehlungen zum Umgang mit Alkohol
Seitz, H. K., & John, U. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01574-2 · Cited by 3
Paradigm shift in steatotic liver disease (SLD): from NAFLD to MASLD
Yoneda, M., Kobayashi, T., Iwaki, M., Wada, N., Nogami, A., Takahashi, H., & Nakajima, A. (2024) · Kanzo · doi:10.2957/kanzo.65.420 · Cited by 2
Reply
Henry, L. L., Paik, J. M., & Younossi, Z. M. (2022) · Hepatology · doi:10.1002/hep.32565 · Cited by 2
“Alternatively, ALD is such strong driver of liver mortality among MAFLD that it dilutes the impact of IR.”
Influential
Effect of Low-Dose Alcohol Consumption on Chronic Liver Disease
Andaloro, S., Mancuso, F., Miele, L., Addolorato, G., Gasbarrini, A., & Ponziani, F. R. (2024) · Nutrients · doi:10.3390/nu16050613 · Cited by 2
“Another study was based on the NHANES database, comprising more than 4000 individuals with evidence of steatosis in abdominal ultrasounds [32].”
Method
Treatment profile and long-term outcome of intensive care unit-admitted patients with liver cirrhosis or other liver disease in relation to alcohol consumption
Hietanen, S., Herajärvi, J., Lehtonen, A., Lahtinen, S., & Liisanantti, J. H. (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2020.1861646 · Cited by 2
Body Mass Index and PNPLA3 Genetic Variant Modify the Association of Alcohol Consumption With Liver Fat Content
Liu, Z., Zhang, X., & Chen, X. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.018 · Cited by 2
Delineating Metabolic Dysfunction-Associated Steatotic Liver Disease and Comorbid Risk With Clinical, Blood and Metabolomic Parameters—A UK Biobank Analysis
Ho, B., Yun Xu, A., Goldring, C. E., Goodacre, R., & Pirmohamed, M. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103537 · Cited by 1
Alcohol-driven phenotypic transition in MASLD and risk of liver-related events
Jang, S., Song, J., Kang, E. S., Cheon, S., Kwak, T., Kim, Y., Kong, S., Choi, J., Kang, M., Khil, J., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101866 · Cited by 1
“45 Although most prior studies were conducted in Western cohorts, our results from a large Asian population support the generalizability of alcohol-related risk across diverse ethnic and healthcare settings.”
Alcohol intake reprograms hepatic immune-metabolic circuits to exacerbate murine atherosclerosis and human cardiovascular risk
Hoebinger, C., Semmler, G., Petrenko, O., Rajcic, D., Hoffelner, D. K., Duckova, T., Baranovskyi, T. P., Göderle, L., Khuu, M. P., Paeslack, N., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101932 · Cited by 1
Biomodeling of mixed origin fatty liver disease
Brus, T. V., Vasiliev, A. G., Кравцова, А. А., Vasilieva, A. V., Brus, Y. S., & Bannova, A. V. (2024) · Pediatrician (St Petersburg) · doi:10.17816/ped625940 · Cited by 1
Alcohol-associated liver disease and behavioral and medical cofactors: unmet needs and opportunities
Monnig, M. A., Padovano, H. T., & Monti, P. M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1322460 · Cited by 1
Análise do consumo de bebidas alcoólicas em acadêmicos da área da saúde / Analysis of alcohol consumption in healthcare students
Paiva, D. D. M. D., Rigo, M. S., Nascimento, L. D. D., Araujo, H. R. G., Lima, E. F. D. F., de Souza, A. K. P., de Sousa, D. H. A. V., & de Arruda, I. T. S. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n1-070 · Cited by 1
Nicht-alkoholische Fettlebererkrankung und Alkoholkonsum
Stickel, F., & Datz, C. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_32 · Cited by 1
Alcohol use in patients with non-alcoholic fatty liver: a tangled web of causality
Brandman, D., & Terrault, N. A. (2019) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.01.07
Reply
Stepanova, M., & Younossi, Z. M. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.07.038 · Cited by 1
Disputes about the efficacy of polyglycolic acid shielding for prevention of bleeding after endoscopic submucosal dissection
Wang, C., Zhao, L., & Fan, Z. (2019) · Endoscopy · doi:10.1055/a-0999-5452
Integrative Proposal for the Use of Biomarkers in Clinical Practice Management of NAFLD/NASH
Benítez, C., Arab, J. P., Francisco Barrera, M., Bañales, J. M., & Arrese, M. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-37173-9_13
Alcohol Consumption in Non-Alcoholic Fatty Liver Disease: Safety and Disease Overlap
Reddy, S. S. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00542-w
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease
Carubbi, F., Lugari, S., Cavicchioli, A., Cassinerio, E., Bursi, S., Motta, I., Cappellini, M. D., Salda, A. D., Andreoné, P., & Nascimbeni, F. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2020.12.034
Issue Highlights
Chang, L. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.022
Recent Updates in the Prevention of Nonalcoholic Fatty Liver Disease
El‐Kassas, M., Awad, A., & Méndez‐Sánchez, N. (2023) · Gene Expression · doi:10.14218/ge.2022.00005s
Diet and Exercise Treatment and Prevention for Non-alcoholic Fatty Liver Diseases Patients
Kong, D. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/3/20220248
“Body mass index(BMI) BMI is a proportion from body weight to height, a comprehensive measurement of body mass and composition[3,5,7,8,9,10].”
Background
Adipositas und NAFLD: Assoziation oder Auslöser?
Roeb, E., & Tacke, F. (2023) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2059-9049
Enhanced Non-Alcoholic Fatty Liver Detection: CT Scan Image Analysis and Noise Reduction with Morphological DilationPreprint
Pithani, K. D., & Vadhi, R. (2023) · Research Square · doi:10.21203/rs.3.rs-3049270/v1
Modulation of Alcohol-Related Liver Disease by Obesity and Diabetes
Hegmar, H., & Hagström, H. (2023) · Springer eBooks · doi:10.1007/978-3-031-32483-3_51
Influencing factors of health risk behavior among those overweight and obesity in ChinaPreprint
Guo, S., Xiong, J., & Su, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-3688113/v1
Future directions for fatty liver disease
Bartolomeo, A. D., & George, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00016-9
Effects of Immature Soybeans on Lipid Metabolism in Rats Fed Normal and High-Fat High-Fructose NAFLD Diets
Mizushige, T., SUZUKI, T., UTSUKI, T., ISHIKAWA, Y., Ogawa, K., Kanamaru, C., Shoji, S., Nogimura, D., Aiso, H., Yoshida, E., et al. (2024) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.70.370
Rehabilitation Treatment for Liver Disease：Our Experience and Future Perspectives
Hashida, R., Kawaguchi, T., & Matsuse, H. (2025) · リハビリテーション医学 : 日本リハビリテーション医学会誌 · doi:10.2490/jjrmc.62.375
Cardiometabolic risk factors and alcohol use among adults aged 20-25: A nationally representative US study
Hodara, E., Dodge, J. L., Terrault, N. A., & Lee, B. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.08.014
Impact of metabolic syndrome components on fibrosis severity and mortality in alcohol-related liver disease
Abassa, K.-K., Yu, H., Tan, S., Li, M., Zhong, Z., Zhou, H., & Guo, Y. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113027
Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment
Bergheim, I., Cadranel, J. F. D., Chen, J., Ding, W., Eferl, R., García‐Ruiz, C., Jaeschke, H., Kazerouni, F., Lonardo, A., Mann, D. A., et al. (2026) · Exploration of Digestive Diseases · doi:10.37349/edd.2026.1005110
Cardiovascular risk and lipid disorders among women using hormonal contraceptives in Gondar Town Northwest Ethiopia
Chane, E., Baynes, H. W., Worede, A., Fetene, G., Mekuanint, A., Eshetu, B., Girma, M., Fentie, A., Feyisa, M. S., Hadgu, R., et al. (2026) · Discover Medicine · doi:10.1007/s44337-026-00591-y
Moderate alcohol consumption and clinical outcomes in MASLD: a systematic review and meta-analysis of longitudinal cohorts
de Souza, N. S., Cotrim, H. P., & de Andrade, A. R. C. F. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04814-5
“The most widely cited hypothesis relates to a potential cardioprotective effect of low alcohol intake, including increases in high-density lipoprotein (HDL) cholesterol, improvements in insulin sensitivity, and attenuation of systemic inflammation, which together may reduce cardiovascular risk [15].”
Influential
Culturally adapted multimodal lifestyle approaches for metabolic dysfunction-associated steatotic liver disease: role of diet, physical activity and sleep
George, E. S., Sood, S., Sualeheen, A., Cartledge, S. H., Roberts, S. K., Daly, R. M., Tan, S., Scott, D., Wheeler, K., George, J., et al. (2026) · Proceedings of The Nutrition Society · doi:10.1017/s0029665126103048
“Individuals with MetALD tend to experience more severe disease progression and have a higher risk of mortality than those without excessive alcohol use (49) .”
GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction
Reitz, J., Rosoff, D. B., Pacher, P., & Lohoff, F. W. (2026) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2026.100793
Liver transplantation in patients with metabolic dysfunction and alcohol-related liver disease (MetALD)
Coronel-Castillo, C. E., Parraga, X., Sierra, L., Arrese, M. A., Arab, J. P., & Díaz, L. A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.78
Alcohol, cardiometabolic risk factors, and cirrhosis: Ten-year risk estimates from a population-based Danish cohort
Rønn, J. H., Jepsen, P., Mellinger, J. L., Innes, H. A., Eliasen, M., Christensen, A. I., Madsen, L. G., & Askgaard, G. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.08.017
The convergent roles of metabolic dysfunction, alcohol, and iron in steatotic liver disease: a review
Akanbi, A., Bridle, K. R., & Crawford, D. H. (2026) · Bioscience Reports · doi:10.1042/bsr20250106
“Current guidelines recommend abstinence even in cases of “moderate” drinking, as binge episodes (even if infrequent) can significantly worsen prognosis [164,165].”

Authors: Younossi, Z. M., Stepanova, M., Ong, J., Yilmaz, Y., Duseja, A., Eguchi, Y., El Kassas, M., Castellanos-Fernandez, M., George, J., Jacobson, I. M., Bugianesi, E., Wong, V. W.-S., Arrese, M., de Ledinghen, V., Romero-Gomez, M., Mendez-Sanchez, N., Ahmed, A., Wong, R., Papatheodoridis, G., Serfaty, L., Younossi, I., Nader, F., Ziayee, M., & Afendy, A.
Affiliations: Inova Health System (US)
Center for Outcomes Research in Liver Diseases (US)
University of the Philippines Manila (PH)
Marmara University (TR)
Post Graduate Institute of Medical Education and Research (IN)
Saga University (JP)
The University of Sydney (AU)
NYU Langone Health (US)
University of Turin (IT)
Chinese University of Hong Kong (HK)
Pontificia Universidad Católica de Chile (CL)
Stanford Medicine (US)
Alameda Health System (US)
Hôpital d'Hautepierre (FR)
Corresponding author: Younossi, Zobair M.
ORCID: Younossi, Zobair M.
Stepanova, Maria
Ong, Janus
Yilmaz, Yusuf
Duseja, Ajay
Eguchi, Yuichiro
George, Jacob
Jacobson, Ira M.
Bugianesi, Elisabetta
Wong, Vincent Wai-Sun
Arrese, Marco
Romero-Gomez, Manuel
Ahmed, Aijaz
Wong, Robert
Serfaty, Lawrence
Venue: Clinical Gastroenterology and Hepatology
Publisher: Elsevier BV
Published: 2019-07
Volume: 17
Issue: 8
Pages: 1625-1633.e1
ISSN: 1542-3565 (ISSN-L)
DOI: 10.1016/j.cgh.2018.11.033
OpenAlex: W2901363517
Cited by: 172
References: 23
Citations by year: 2026: 13 · 2025: 18 · 2024: 37 · 2023: 23 · 2022: 19 · 2021: 22 · 2020: 24 · 2019: 16
FWCI: 12.10
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Clinical Gastroenterology and Hepatology (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
Dspace Repository (Marmara Üniversitesi) (submittedVersion, other-oa)
Dspace Repository (Marmara Üniversitesi) (submittedVersion)
Funders: Center for Outcomes Research in Liver Disease
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords: non-alcoholic fatty liver disease, hepatic steatosis, alcohol consumption, metabolic syndrome, mortality, excessive drinking, all-cause mortality, cause-specific mortality, liver disease progression, NHANES III, mortality risk factors, alcohol screening and brief intervention
MeSH terms: Adult, Aged, Alcohol Drinking, Female, Follow-Up Studies, Humans, Liver Cirrhosis, Alcoholic, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, United States, Incidence, Survival Rate, Disease Progression, Metabolic Syndrome, Young Adult, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks